Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in Schizophrenia
NCT07686263Phase 3Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 7
01
Overview
A Phase 3 trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07686263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686263.